News Releases

Break Wave™ First-in-Human Multicenter Clinical Trial publication selected as the cover article of the Journal of Urology, October 2024 issue. (Article PDF, Journal of Urology Press Release, Infographic Result Summary PPT Download)

Ultrasound propulsion reduces relapse rate incidence by 70% in patients with post-lithotripsy residual fragments as shown in the University of Washington randomized controlled trial published in Journal of Urology (Article PDF, Urology Times Interview)

Best Endourology/Stone Paper – University of Washington’s “Randomized Controlled Trial of Ultrasonic Propulsion–Facilitated Clearance of Residual Kidney Stone Fragments vs Observation” highlighted as the best paper in Stone Disease at the World Congress of Endourology 2024 conference.

Come visit the SonoMotion booth at the American Urological Association conference in San Antonio, TX on May 3-5, 2024 (Booth #1222).

Best of EAU24 Abstracts – SonoMotion’s Break Wave First-In-Human clinical results to be featured at the EAU24 plenary session “Best of EAU24 Abstracts: An expert discussion” on Monday, April 8, 2024.

Strong presence at the European Association of Urology conference with two Break Wave presentations, including (i) First-In-Human clinical trial results by Dr. Ben Chew and (ii) “Advances in technology – Burst-wave lithotripsy: All set?” by Dr. Mehmet Özsoy.

SonoMotion initiates Break Wave pivotal trial (SOUND) at ten sites in the United States and Canada.

SonoMotion receives FDA Breakthrough Device Designation for Break Wave™ procedure.